Classification and Prediction of Difficult Awake Tracheal Intubation With Flexible Bronchoscopes
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Apr 29, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called awake tracheal intubation using flexible bronchoscopes, which is a technique used to help patients breathe when there are expected difficulties with their airways. The goal is to create new ways to predict how challenging this procedure might be, both before it starts and after it has been performed. Currently, doctors often rely on older scoring systems that may not be suitable for this specific method. By developing new prediction models and using advanced technology, the researchers hope to improve safety and effectiveness during this important airway management technique.
To participate in this trial, patients must be at least 18 years old and have a known risk for difficult airways, meaning they are likely to need the awake tracheal intubation procedure. Participants will need to give their consent to join the study. Unfortunately, individuals who are pregnant, breastfeeding, or not scheduled for the procedure will not be eligible. If you choose to participate, you can expect to contribute to the development of better tools that could help doctors manage airway difficulties in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with an anticipated difficult airways scheduled for ATI:FB
- • Consent by the patient
- • Minimum 18 years of age
- Exclusion Criteria:
- • Patients not scheduled for ATI:FB
- • Pregnant or breastfeeding patients
- • Consent not given by the patient
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Trial Officials
Martin Petzoldt, MD, FEAMS
Principal Investigator
University Medical Center Hamburg-Eppendorf: Universitatsklinikum Hamburg-Eppendorf
Vera Köhl, MD
Principal Investigator
University Medical Center Hamburg-Eppendorf: Universitatsklinikum Hamburg-Eppendorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported